New drug cocktail shows promise for Hard-to-Treat leukemia

NCT ID NCT03862157

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 participants will receive the drugs intravenously or by mouth. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

azacitidine, venetoclax, and pevonedistat

What this could lead to

If successful, this combination could offer a new treatment option for people with hard-to-treat acute myeloid leukemia, potentially improving remission rates.

What could go wrong

This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the combination may not work better than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera acute myeloid leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative cellular phase chronic idiopathic myelofibrosis chronic eosinophilic leukemia chronic myelomonocytic leukemia chronic neutrophilic leukemia essential thrombocythemia hypereosinophilic syndrome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative neoplasm myeloid neoplasm Myeloproliferative Disorders myeloproliferative neoplasm myeloproliferative neoplasm, unclassifiable primary myelofibrosis thrombocytosis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE CHRONIC EOSINOPHILIC LEUKEMIA, NOT OTHERWISE SPECIFIED CHRONIC MYELOMONOCYTIC LEUKEMIA CHRONIC NEUTROPHILIC LEUKEMIA ESSENTIAL THROMBOCYTHEMIA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH RING SIDEROBLASTS AND THROMBOCYTOSIS MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE MYELOID NEOPLASM MYELOPROLIFERATIVE NEOPLASM MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE OVERT PRIMARY MYELOFIBROSIS POLYCYTHEMIA VERA POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE PREFIBROTIC/EARLY PRIMARY MYELOFIBROSIS

Contacts and locations

Show contact details

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States